Anaptysbio (ANAB) Change in Accured Expenses (2016 - 2025)
Anaptysbio's Change in Accured Expenses history spans 10 years, with the latest figure at -$22.4 million for Q4 2025.
- For Q4 2025, Change in Accured Expenses rose 44.04% year-over-year to -$22.4 million; the TTM value through Dec 2025 reached -$87.3 million, down 158.08%, while the annual FY2025 figure was -$87.3 million, 158.08% down from the prior year.
- Change in Accured Expenses reached -$22.4 million in Q4 2025 per ANAB's latest filing, down from -$18.6 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $8.5 million in Q1 2023 to a low of -$40.0 million in Q4 2024.
- Average Change in Accured Expenses over 5 years is -$5.3 million, with a median of -$844500.0 recorded in 2021.
- Peak YoY movement for Change in Accured Expenses: soared 8706.67% in 2023, then crashed 2573.36% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at -$5.3 million in 2021, then skyrocketed by 190.81% to $4.8 million in 2022, then crashed by 131.0% to -$1.5 million in 2023, then plummeted by 2573.36% to -$40.0 million in 2024, then soared by 44.04% to -$22.4 million in 2025.
- Per Business Quant, the three most recent readings for ANAB's Change in Accured Expenses are -$22.4 million (Q4 2025), -$18.6 million (Q3 2025), and -$22.3 million (Q2 2025).